✦ LIBER ✦

The Influence of Cryopreservation on Activity and Surface Markers of Lymphokine-Activated Killer Cells

✍ Scribed by C. Letellier; L. Rameliarison; D. Fizet; A.M. Ferrer; G. Vezon

Book ID: 115109641
Publisher: John Wiley and Sons
Year: 1991
Tongue: English
Weight: 644 KB
Volume: 61
Category: Article
ISSN: 0042-9007
DOI: 10.1111/j.1423-0410.1991.tb00252.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Differential effect of cryopreservation

Differential effect of cryopreservation on natural killer cell and lymphokine-activated killer cell activities

✍ F. Martí; A. Miralles; M. Peiró; B. Amill; C. de Dalmases; G. Piñol; F. Rueda; J 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 529 KB

Induction of lymphokine-activated killer

Induction of lymphokine-activated killer and natural killer cell activities from cryopreserved lymphocytes

✍ H. Kawai; A. Komiyama; M. Katoh; A. Yabuhara; Y. Miyagawa; T. Akabane 📂 Article 📅 1988 🏛 Elsevier Science 🌐 English ⚖ 464 KB

In vitro and in vivo activity of murine

In vitro and in vivo activity of murine lymphokine-activated killer cells after cryopreservation

✍ I. G.H. Schmidt-Wolf; M. Aihara; R. S. Negrin; K. G. Blume; N. J. Chao 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 409 KB

Effect of ouabain on lymphokine-activate

Effect of ouabain on lymphokine-activated killer cells

✍ B. Olej; L. de La Rocque; F.P.D. Castilho; I.F. Mediano; M.M. Campos; V.M. Rumja 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 456 KB

Lymphokine-activated killer cells in rat

Lymphokine-activated killer cells in rats: Generation of natural killer cells and lymphokine-activated killer cells from bone marrow progenitor cells

✍ Mariana Sarneva; Nikola L. Vujanovic; M.R.M. van den Brink; Ronald B. Herberman; 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 706 KB

Immunotherapy of cancer with lymphokines

Immunotherapy of cancer with lymphokines and lymphokine-activated killer cells

✍ John W. Yarbro 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 996 KB

Our expanding knowledge of the immune system has provided a basis of rationality for immunotherapy . Some non-specific immunotherapy has achieved the status of standard treatment: interferon in hairy cell leukemia and chronic myelogenous leukemia, BCG in bladder cancer, and levamisole in colon cance